125 related articles for article (PubMed ID: 9207942)
1. A new rational hypothesis for the pharmacophore of the active metabolite of leflunomide, a potent immunosuppressive drug.
Bertolini G; Aquino M; Biffi M; d'Atri G; Di Pierro F; Ferrario F; Mascagni P; Somenzi F; Zaliani A; Leoni F
J Med Chem; 1997 Jun; 40(13):2011-6. PubMed ID: 9207942
[TBL] [Abstract][Full Text] [Related]
2. The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.
Davis JP; Cain GA; Pitts WJ; Magolda RL; Copeland RA
Biochemistry; 1996 Jan; 35(4):1270-3. PubMed ID: 8573583
[TBL] [Abstract][Full Text] [Related]
3. The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage.
Kobayashi Y; Ueyama S; Arai Y; Yoshida Y; Kaneda T; Sato T; Shin K; Kumegawa M; Hakeda Y
J Bone Miner Metab; 2004; 22(4):318-28. PubMed ID: 15221489
[TBL] [Abstract][Full Text] [Related]
4. Leflunomide and malononitrilamides.
Silva Júnior HT; Morris RE
Am J Med Sci; 1997 May; 313(5):289-301. PubMed ID: 9145039
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of leflunomide in Chinese healthy volunteers.
Li J; Yao HW; Jin Y; Zhang YF; Li CY; Li YH; Xu SY
Acta Pharmacol Sin; 2002 Jun; 23(6):551-5. PubMed ID: 12060531
[TBL] [Abstract][Full Text] [Related]
6. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes.
Kalgutkar AS; Nguyen HT; Vaz AD; Doan A; Dalvie DK; McLeod DG; Murray JC
Drug Metab Dispos; 2003 Oct; 31(10):1240-50. PubMed ID: 12975333
[TBL] [Abstract][Full Text] [Related]
7. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.
Chong AS; Huang W; Liu W; Luo J; Shen J; Xu W; Ma L; Blinder L; Xiao F; Xu X; Clardy C; Foster P; Williams JA
Transplantation; 1999 Jul; 68(1):100-9. PubMed ID: 10428276
[TBL] [Abstract][Full Text] [Related]
8. Inhibiting effects of Leflunomide metabolite on overexpression of CD147, MMP-2 and MMP-9 in PMA differentiated THP-1 cells.
Huang JL; Wu SY; Xie XJ; Wang MX; Zhu S; Gu JR
Eur J Pharmacol; 2011 Nov; 670(1):304-10. PubMed ID: 21871883
[TBL] [Abstract][Full Text] [Related]
9. Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases.
Mangold U; Dax CI; Saar K; Schwab W; Kirschbaum B; Müllner S
Eur J Biochem; 1999 Dec; 266(3):1184-91. PubMed ID: 10583416
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of beta-hydroxy-propenamide derivatives and the inhibition of human dihydroorotate dehydrogenase.
Kim TH; Na HS; Löffler M
Arch Pharm Res; 2003 Mar; 26(3):197-201. PubMed ID: 12723931
[TBL] [Abstract][Full Text] [Related]
11. A 771726, the active metabolite of leflunomide, inhibits TNF-alpha and IL-1 from Kupffer cells.
Yao HW; Li J; Chen JQ; Xu SY
Inflammation; 2004 Apr; 28(2):97-103. PubMed ID: 15379215
[TBL] [Abstract][Full Text] [Related]
12. In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice.
Xu X; Blinder L; Shen J; Gong H; Finnegan A; Williams JW; Chong AS
J Immunol; 1997 Jul; 159(1):167-74. PubMed ID: 9200452
[TBL] [Abstract][Full Text] [Related]
13. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner.
Hamilton LC; Vojnovic I; Warner TD
Br J Pharmacol; 1999 Aug; 127(7):1589-96. PubMed ID: 10455314
[TBL] [Abstract][Full Text] [Related]
14. The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function.
Kirsch BM; Zeyda M; Stuhlmeier K; Grisar J; Smolen JS; Watschinger B; Stulnig TM; Hörl WH; Zlabinger GJ; Säemann MD
Arthritis Res Ther; 2005; 7(3):R694-703. PubMed ID: 15899055
[TBL] [Abstract][Full Text] [Related]
15. The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical review.
Schattenkirchner M
Immunopharmacology; 2000 May; 47(2-3):291-8. PubMed ID: 10878295
[TBL] [Abstract][Full Text] [Related]
16. Oral administration of leflunomide (HWA486) results in prominent suppression of immunoglobulin E formation in a rat type 1 allergy model.
Mizushima Y; Amano Y; Kitagawa H; Ogata K
J Pharmacol Exp Ther; 1999 Feb; 288(2):849-57. PubMed ID: 9918599
[TBL] [Abstract][Full Text] [Related]
17. Suppressive effect of leflunomide on rat hepatic stellate cell proliferation involves on PDGF-BB-elicited activation of three mitogen-activated protein kinases.
Si HF; Lv X; Guo A; Jiang H; Li J
Cytokine; 2008 Apr; 42(1):24-31. PubMed ID: 18343153
[TBL] [Abstract][Full Text] [Related]
18. [Inhibition of leflunomide active metabolite A771726 on high glucose-induced podocyte apoptosis].
Yuan YC; Yu WM; Li RS; Qiao X
Zhonghua Yi Xue Za Zhi; 2011 Mar; 91(10):703-6. PubMed ID: 21600180
[TBL] [Abstract][Full Text] [Related]
19. The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1.
Moon SJ; Kim EK; Jhun JY; Lee HJ; Lee WS; Park SH; Cho ML; Min JK
J Transl Med; 2017 Feb; 15(1):31. PubMed ID: 28193225
[TBL] [Abstract][Full Text] [Related]
20. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
Bohanec Grabar P; Grabnar I; Rozman B; Logar D; Tomsic M; Suput D; Trdan T; Peterlin Masic L; Mrhar A; Dolzan V
Drug Metab Dispos; 2009 Oct; 37(10):2061-8. PubMed ID: 19581389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
